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In English
European marketing authorisation procedures –
scope for further development
Pekka Kurki
Head of Department, Professor
National Agency for Medicines
Editorial
Innovative new medicinal products in the European
Union are assessed according to the centralised
procedure coordinated by the European Medicines
Agency, EMEA. Marketing authorisation applica-
tions for other medicines are mainly managed in
the decentralised and mutual recognition proce-
dures which are based on the mutual collaboration
of the national agencies. Nowadays the national
marketing authorisation procedure is mainly fo-
cused on the maintenance of old authorisations and
the evaluation of authorisations for generic medici-
nal products (future reference member state duties).
Rational sharing of work among the national medi-
cines agencies is the aim intended by the EU com-
mon procedures. The goal is to avoid overlapping
work, in order to have adequate expert resources
available for execution of new regulatory duties
and to improve the quality of regulation.
Common EU procedures rely on the network of
medicines agencies, with EMEA playing the central
role. The network model has several advantages in
a community like the EU, where the organisation
of healthcare, the traditions of pharmacotherapy
and the disease epidemiology vary from one mem-
ber state to another. The future of the network
model is dependent on whether the member states
wish to contribute to the mutual collaboration by-
offering their best expertise for tasks which involve
other member states of the EU.
Marketing authorisation applications and appli-
cations for variations to the authorisations are fast
growing in number. Increased demands on quality
assurance and openness, and arbitration procedures
associated with disputes between member states
make the marketing authorisation processes ever
more complicated. Increasing measures are re-
quired from the regulatory authorities to improve
the availability of medicines, including medicinal
products for children and orphan drugs. The extent
of scientific and general advice for small- and medi-
um-sized businesses has constantly increased. The
implementation of the regulation of developed ther-
apies (gene and cell therapy, tissue engineering) will
commence in 2008. This regulation requires the
setting up of a new committee within EMEA and,
for example, the evaluation of medicinal products
while they are still under development.
EU marketing authorisation procedures have
generally worked well. Indications of overloading
of the system have nevertheless started to emerge in
recent years. The problem is also due to causes oth-
er than the increased number of applications and
regulatory responsibilities. The operation of the
medicines regulatory network relies upon the na-
tional medicines agencies to take on tasks on behalf
of other member states. This principle has not been
fully followed, but instead, the mutual responsibili-
ties are shared by too few medicines agencies.
A lack of resources and expertise at EU level
may hinder a state from operating as a rapporteur
or as a reference member state in the centralised,
decentralised or mutual recognition procedures.
The lack of contributions may also be explained by
the heavy responsibilities involved in the proce-
dures which the reference or rapporteur state will
have to accept. The heavy assessment process in re-
spect of the centralised procedure can be justified
by the extent of evaluation, by the innovativeness
of the drugs under evaluation, and by the genuine
intention to listen carefully to the applicant and the
experts. The decentralised and mutual recognition
procedures involve national interests and, at worst,
mutual lack of trust among the authorities. Com-
mon decisions sometimes require harmonisation of
national regulatory principles and even of treat-
ment practices, while the member states generally
show great reluctance to accept this.
We have a situation at present, where agencies
that are active in reference member state duties
have one after the other been forced to accept that
they are no longer coping with the processing,
within the due period, of the applications for mar-
keting authorisations submitted to them. NAM has
also been immersed in a severe backlog of applica-
tions. Analysis of the situation is followed by a
conclusion that the operational procedures should
be changed by streamlining, prioritising and au-
tomating the assessment and administration of ap-
plications. A paper in this issue of TABU describes
the status of marketing authorisation procedures
and a strategy for reinstating a marketing authori-
sation application procedure which is able to re-
spect the due dates without jeopardising the safety
of medicines or NAM’s strategic aims.
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Recent developments in pharmaceutical policy
Several reforms have been made
in the Finnish pharmaceutical
service in recent years, focusing
on the management of pharma-
ceutical costs in particular. Con-
cern for the rise in pharmaceuti-
cal costs has increased with the
introduction of expensive new
drugs onto the market and an
ageing population. In the Gov-
ernment Programme (1) of Prime
Minister Matti Vanhanen’s sec-
ond Cabinet, the definitions of
pharmaceutical policy emphasise
cost-effectiveness and restraining
the rising costs but also focus on
safe pharmacotherapy, securing
extensive pharmaceutical service
and introducing a just ceiling sys-
tem with regard to client charges
in social and health care services
(1). 
Restraints on drug costs  
In 2005, pharmaceutical costs
represented 16,3% of the total
healthcare expenditure (2), and
in the first years after 2000, real
annual growth in costs was be-
tween 4% and 8%. Pharmaceuti-
cal policy measures taken in re-
cent years have nevertheless
yielded at least short-term results
in cutting pharmaceutical costs.
In the year 2006, the wholesale
value of outpatient drugs de-
creased for the first time for dec-
ades. This resulted from the 5%
cut, implemented at the begin-
ning of 2006, in wholesale prices
for refunded drugs, as well as
from drug price competition
which was partly influenced by
increased generic substitution in
2006. The strategy of the Min-
istry of Social Affairs and Health
(MSAH) (3) has even set the an-
nual real growth limit for refund-
ed drug costs at 5% for the years
2008 to 2011.
A working group focusing on
a reference price system for drugs
investigated preliminarily two
main models and their effective-
ness in the medicine reimburse-
ment costs. In the generic model,
the preparations are grouped on
the basis of the active substance,
whereas in the therapeutic model
they are grouped according to
their therapeutic equivalence. The
working group considered it pos-
sible to implement the generic
model in a few years’ time (4).
Switching to a reference price
system would follow the general
European trend and be a consis-
tent continuation of the generic
substitution system adopted in
2003.
Improved cost-effectiveness
The main pharmaceutical objec-
tive within the strategy of the
MSAH (3) consists of increasing
the cost-effectiveness of pharma-
ceutical services, for example by
creating incentives to promote ra-
tional prescribing practices. Cost-
effectiveness could also be en-
hanced by increasing the market
share of generic products, which
at present is smaller in Finland
than in many other European
countries (5).
The present government aims
to reform the drug reimburse-
ment system in a cost-containing
manner, but the importance of
cost-effectiveness will also be
recognised, particularly with re-
gard to new medicines (1). As-
sessing cost-effectiveness would
nevertheless require an increased
level of capacity, especially in
health economics (5). Pricing and
reimbursement policy and assess-
ment of the relative effectiveness
of medicines are at present cen-
tral themes also in the European
Union’s pharmaceuticals policy
(6). 
The Pharmaceuticals Pricing
Board decided in 2006 to restrict
reimbursement of two of the
most expensive anti-cholesterol
agents. The restriction contained
a novel requirement according to
which the patient must, under
certain conditions, be switched
to another active substance of
the same drug group. The moti-
vation for the decision was the
marginal additional benefit ob-
tained from the most expensive
statins compared to the extra
costs involved (7). In 2007 the
Pricing Board, exercising for the
first time the right granted by the
Sickness Insurance Act reform,
discontinued reimbursability of a
drug still covered by a product
patent in several other EU coun-
tries (8). 
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Other recent themes
Problems associated with respon-
sibility for covering the costs of
medicines may result in inappro-
priate decisions shifting responsi-
bility for care and costs to anoth-
er funding channel (3). The com-
plicated system of public funding
of pharmacotherapy services
should undergo a total reform, so
that irrespective of the distribu-
tion area, sickness insurance
should compensate for all drugs
covered by the reimbursement
system, and the municipalities
would continue to cover the costs
for all non-refundable outpatient
drugs (9). 
The reform of the Sickness In-
surance Act that came into force
on 1.1.2006 fulfilled several of
the objectives of the pharmaceuti-
cal policy. The drug refund sys-
tem was largely revised. A reform
of the Medicines Act that came
into force on 1.2.2006 prevented
pharmaceutical companies and
pharmacies from establishing re-
bate agreements with pharmacies.
In 2006, licensed sales of over-
the-counter nicotine replacement
products were allowed outside
pharmacies. A three-year trial of
selectively reimbursing the costs
of dose dispensing service was
launched by the MSAH in 2005
and can be expected to continue.
Adoption of electronic prescrip-
tions is also expected to improve
individual patients’ medication
management. The Act on Elec-
tronic Prescriptions came into
force on 1.4.2007, but there will
be a four-year transitional period
before the system is fully imple-
mented. 
Pharmaceutical policy in the
present term of government
Concern for rising pharmaceuti-
cal costs is reflected in the policy
definitions of the present govern-
ment (1). The government is
committed to curbing the rising
costs, and some type of reference
price system is likely to be intro-
duced. In addition to costs, the
government platform will also
tackle cost-effectiveness, which
reflects the shift of attention from
drug prices to the functionality of
the entire treatment chain. With
developed pharmacotherapies it is
possible to achieve cost savings,
for example, as a result of a long-
term reduction in the need for in-
stitutionalised care and improved
employability.
A government platform that
highlights the promotion of safe
pharmacotherapy and the safe-
guarding of extensive pharmaceu-
tical services can be considered a
significant statement of principle.
The pharmaceutical services will
be secured by developing the sys-
tem of subsidiary pharmacies and
licensed medicine chests (10).
In the present term of govern-
ment the relevance of the Phar-
maceuticals Pricing Board as a
pharmaceutical policy operator is
greater than before. The func-
tioning of the Pricing Board has
nevertheless been criticised for
lack of transparency in its deci-
sion-making procedures. It has
even been suggested that the pric-
ing and reimbursement decisions
be separated from the assessment
of therapeutic value of a drug by
establishing an independent
agency for the latter (5). Im-
proved definitions of criteria and
more detailed decisions from the
Board would increase the open-
ness and transparency of the
process (5). Potential for in-
creased coordination of expertise
and assessment of cost-effective-
ness of drugs are indeed to be re-
viewed in the present term of
government (11).
The aims defined in the pre-
sent government platform (1) and
the strategy of the MSAH (3) are
in line with the key objectives of
the document Pharmaceutical
Policy 2010 (12), in particular as
regards appropriate drug use,
reasonable drug costs, safe phar-
macotherapy, regional availability
of pharmaceuticals and promo-
tion of Finnish pharmaceutical
research. Current issues of inter-
est also include problems of the
pharmaceutical services men-
tioned in Pharmaceutical Policy
2010, such as rapidly rising costs,
a two-channelled public funding
system, and possible delays in in-
troduction of new drugs onto or
their total absence from the
Finnish market.
The Finnish pharmaceutical
policy can be considered consis-
tent as far as major definitions of
policy are concerned, but its con-
sistency has in recent years been
reduced by measures aimed at
cost restriction which have often
been introduced quickly. For a
successful pharmaceutical policy,
perseverance and improved pre-
dictability are required. The bet-
ter the pharmaceutical sector is
able to predict the direction of
change, the easier it will be to
prepare for reforms and ensure
uninterrupted pharmaceutical ser-
vices.
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A course of treatment with terbi-
nafine, even one lasting for
months, does not cause a prob-
lem in 90 out of 100 patients.
Stomach complaints, taste distur-
bances or drug-induced rash may,
however, occur in the remaining
10. Other adverse drug reactions
are rare, and severe ones are very
rare.
Stomach complaints
There is no stomach complaint
typical of terbinafine alone. The
symptoms may include pain, diar-
rhoea, and/or flatulence. It would
be a good idea to take terbinafine
with food, even though this is not
an official recommendation. The
absorption of the drug is slightly
improved when taken with food
(below 20% increase in the
AUC), and the risk of stomach
complaints is probably reduced.
Disappearance of the sense of
taste 
A change in or loss of the sense
of taste during a course of terbin-
afine therapy is possible, but it is
almost without exception tran-
sient; it resolves within 1 to 2
months. A disturbance in the
sense of taste is often associated
with the long-term treatment of
onychomycosis, but it is also pos-
sible with only a two-week
course of treatment. 
I have advised my patients to
complete the whole course of
treatment even if their sense of
taste is lost; withdrawal of the
course would jeopardise the re-
sult of the treatment. During my
15 years of experience in pre-
scribing terbinafine, none of my
patients so far has reported a per-
manent taste disorder.
There are isolated reports of
impairment of the sense of smell
during a course of treatment – 
often in association with a distur-
bance of the sense of taste.
Skin reactions
It is well known that oral terbi-
nafine can cause skin reactions.
Their morphology is usually simi-
lar to that of urticaria, exanthe-
ma and Erythema multiforme.
Through the years, AGEP (Acute
Generalized Exanthematous Pus-
tulosis) has also become to be in-
cluded among these, as a rare re-
action.
Statistically the risk of devel-
oping the condition of Erythema
multiforme major, i.e. the 
Stevens-Johnson syndrome is
1:350,000 and that of Lyell’s syn-
drome (Toxic epidermal necroly-
sis) even smaller.
If the patient reports having
had a rash during a course of
terbinafine therapy, the course
should be discontinued immedi-
ately and not reinstated until the
type of the skin symptom is as-
sessed by actually meeting the pa-
tient face to face.
On the one hand, the effec-
tiveness of medication with
terbinafine is not being impaired
through the temporary discontin-
uation of the medication, and on
the other, not all rashes during
medication are caused by the
drug itself. To try to ‘identify’ the
skin symptom by telephone is al-
so quackery in such a case.
Rare severe adverse reactions
Even though terbinafine can
cause severe disturbances of the
blood count and liver function,
these are rare enough for no lab-
oratory monitoring to be neces-
sary during the course of treat-
ment. Earlier liver problems
should be taken into account and
possible clinical symptoms should
be noted. 
Interactions
Even though terbinafine is never-
theless not entirely free of the risk
of interactions, it is harmless in
comparison with the azole drugs.
The concentration of drugs using
the CYP2D6 system in their me-
tabolism may (mainly based on
the information gained through
in vitro studies) increase during
terbinafine therapy, but I have
not encountered any problems
with patients receiving for exam-
ple, beta-blockers. If the patient
uses drugs metabolised by CYP-
2D6 with a narrow therapeutic
window, it is recommended that
the details of interactions con-
tained in the SPC be closely
checked.
Adverse reactions in Finland?
From the year 2000 to the end of
April 2007 a total of 123 reports
concerning terbinafine were re-
ceived by the National Adverse
In English
Terbinafine – a matter of taste
Terbinafine, topically or orally used, is an effective drug in the treatment of  dermatophytosis. It is a
fungicide, but not completely free of  harmful adverse effects. Most of the harmful effects of
terbinafine were already known when it was registered by the British for the first time in 1991.
Raimo Suhonen
PhD, Professor
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Drug Reaction database in Fin-
land. During the same period,
daily doses (250 mg) of oral
terbinafine were sold in Finland
amounting to 17.8 million. On
the assumption that all adverse
reactions have been reported, the
intake of one tablet is conse-
quently associated with an ad-
verse reaction risk of about 0.7
per thousand. As the majority of
the sales was principally of pack-
ets of 28 tablets, the most com-
mon therapeutic indication is
probably onychomycosis, the rec-
ommended length of treatment
with terbinafine is 3 months = 3
x 28 tablets. Based on the infor-
mation available on this register
the course of treatment for der-
matophytes therefore appears to
be associated with a less than
0.1% risk of adverse reactions.
Previous clinical studies actu-
ally show the real risk of adverse
reactions to be about 10%. The
purpose of an adverse drug reac-
tion register is, in fact, detecting
unexpected, serious and less com-
mon reactions. Since terbinafine
actually was in use in Finland for
about ten years prior to the re-
porting period mentioned, stom-
ach complaints and disturbances
in the sense of taste usually fall
below the reporting threshold.
One would imagine that along
with the patent for terbinafine
having become outdated, the
dropped price would have in-
creased both its use and the ad-
verse reactions. However, the to-
tal sales of the drug remain un-
changed. That’s as it should be.
The true effectiveness of the
treatment?
I promise to patients suffering
from dermatophyte infection of
the skin that the disease is defi-
nitely resolved with terbinafine –
at least after an oral intake, if
topical treatment is not sufficient
in that specific case. The same
can be promised about finger
nails, but the prognosis for ony-
chomycosis of toe nails, which
grow three times slower, can be
judged by tossing a coin. The av-
erage chance of a full recovery
from toenail onychomycosis is
tantamount to ‘heads or tails’.  
The usual dermatophytes in
between the 4th and 5th toes
ought not to be treated with oral
terbinafine; topical treatment will
cure them. If not, dermatophyte
infection is the incorrect diagno-
sis or there is something else also
wrong with the skin as well. If
dermatophytes are present on the
sole of the foot, they will not re-
solve with topical antifungal –
but they will be alleviated – and
will thereafter spread to the nails,
too.
What about the treatment 
alternatives?
In principle, topical treatment
alone could of course be consid-
ered for both the dermatophytes
of the skin and the nails. Howev-
er, topical treatment for the nails
is only effective in the most mild
cases of distal infections. Nor
should the strong, 28% tiocona-
zole solution be used in their
treatment; it probably causes
more drug allergies than it cures.
Amorolfine lacquer is at least less
harmful.
A case of its own is represent-
ed by a south-west Finnish ‘anti-
fungal’ preparation, which is not
burdened by research evidence or
the drug advertising rules that
medicinal products are governed
by. 
Should a diagnosed disease
always be treated with drugs?
Should a doctor actively offer a
drug for the treatment of ony-
chomycosis of which he has made
a diagnosis ‘in passing’. Will a
spreading outbreak of onychomy-
cosis occur if it is left untreated?
When even by trying hard and
with optimal growing conditions
for the fungi as many as 50% of
the cultivation samples are incor-
rect negatives, I find it hard to
believe that dermatophytes of the
nail would jump from the nail to
one’s own skin, let alone that of
close relatives.
At least as far as the elderly
on a multitude of drug therapies
are concerned, it is advisable to
use common sense when consid-
ering long courses of treatment
for onychomycosis.
How can the adverse 
reactions caused by
terbinafine be reduced?
According to practical experi-
ence, oral antifungals are pre-
scribed with inadequate evidence
for the role of dermatophyte in
the clinical symptoms. If the diag-
nosis of dermatophytosis (infec-
tion caused by a dermatophyte) is
unclear, a therapeutic trial with
an oral antifungal should not be
performed. Unnecessary treat-
ment exposes the patient to un-
necessary risk for adverse drug
reactions. In the case of a serious
adverse drug reaction the situa-
tion of the doctor is also lamenta-
ble if there is no real reason for
the treatment.
We all make wrong diagnoses.
In dermatophytosis they can be
reduced by taking fungal samples.
If treatment is urgently required –
which is seldom the case in a der-
matophytosis – direct microscopy
of the specimen may provide an
additional clue to the clinical as-
sessment, sometimes even evi-
dence enough for the start of the
therapy. It is nevertheless only a
fungal culture that confirms the
diagnosis and the species of the
fungus, which especially in scalp
infections has an effect at least on
the length of the medical treat-
ment.
Fungal specimen are also asso-
ciated with their own sources of
errors. The specimen may be tak-
en from a non-representative site
or may be inadequate. The sam-
ple collector should be well ac-
quainted with her job.
Repeated minimal nail injury,
caused by unfitting shoes, may
cause onycholysis. This must not
be interpreted and treated as ony-
chomycosis.
In English
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Articaine-containing local anaesthetics and 
sensory disturbances
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A sensory loss (hypoaesthesia) is
manifested as impaired tactile
sense, whereas sensory changes
(paraesthesia) are manifested as
tactile hallucinations such as
burning or stinging. Paraesthesia
may also be associated with hy-
peraesthesia, increased sensibility
or dysaesthesia, changed sensory
sensitivity. In addition to adverse
reactions caused by articaine-con-
taining local anaesthetics in asso-
ciation with dental procedures
published in the literature, we
will discuss in this article also
those reported to the adverse
drug reaction register of NAM
(National Agency for Medicines).
Articaine has been in use in
Finland for over 20 years. Local
anaesthetics containing articaine
are available on the market under
three different trade names: Sep-
tocaine, Ultracain D-Suprarenin
and Ubistesin. These products
contain 40 mg/ml articaine and 5
microg/ml or 10 microg/ml adre-
naline. Adrenaline is used becau-
se of its vasoconstrictive effect,
i.e. it contracts the blood vessels.
Vasoconstriction slows down the
absorption of articaine resulting
in a higher concentration at the
injection site and prolongation of
the duration of effect.
Products containing articaine
can be used for both infiltration
and nerve block anaesthesia. In
infiltration anaesthesia the anaes-
thetic agent is injected into the
area of the procedure, and in
nerve block anaesthesia adjacent
to a nerve supplying the area of
the procedure. For example,
anaesthesia is achieved in the
teeth of the lower jaw by nerve
block anaesthesia of the inferior
alveolar nerve up to the midline
of the lower jaw on the side
which is to be anaesthetized.
Generally the lingual nerve is also
anaesthetized due to its close
proximity. The amount usually
used in local anaesthesia, e.g. in
association with tooth removal, is
one ampoule (1.7 ml) of an arti-
caine preparation, which contains
68 mg of articaine. The effect
starts within a couple of minutes
and usually lasts for about 2
hours following infiltration an-
aesthesia and up to 4 hours fol-
lowing nerve block anaesthesia.
Once introduced onto the
market, articaine achieved popu-
larity because it contained preser-
vaties that were less likely to
cause allergy than those included
in other local anaesthetic agents
in use at the time. A similar dif-
ference does not exist anymore
for example, with lidocaine.  In
principle, articaine is a safer local
anaesthetic than lidocaine due to
its shorter half-life. In compari-
son with other amide-containing
local anaesthetics, articaine has a
broader therapeutic spectrum
which consequently permits the
use of higher concentrations (arti-
caine 4% vs. lidocaine 2%), re-
sulting in a smaller volume of in-
jection of the local anaesthetic
being administered.
Consumption of dental local
anaesthetics 
In 2006 the consumption of
products containing articaine to-
talled 2,193,150 cylinder am-
poules (the volume of one am-
poule being 1.7 ml) and sales
have been constantly increasing
since the year 2000 (Fig.).
Local anaesthesia in dental procedures is estimated to be associated with a 0.15%–0.54% risk of
transient sensory losses and changes. Permanent sensory losses occur significantly less frequently, 
in 0.0001%–0.01% of local anaesthetic procedures. In comparison with other anaesthetics, more 
frequent local nerve injuries are suspected to have been caused by articaine (1).
0
500 000
1 000 000
1 500 000
2 000 000
2 500 000
2002 2 003 2 004 2 005 2 006
N
um
be
ro
fc
yl
in
de
rp
ac
ka
ge
s
Articaine, combinations Lidocaine, combinations Prilocaine, combinations
Fig. The sale of dental local anaesthetics in the form of cylinder 
ampoules in 2002–2006.
TABU 6. 2007 59
In English
Reports of adverse reactions
A total of 84 adverse reactions
caused by dental local anaesthet-
ics were reported to the National
Agency for Medicines up until
the end of October 2007. Ad-
verse drug reaction reports re-
ceived on products containing ar-
ticaine totalled 52, and they in-
cluded 82 different reactions
(Table 1). The most frequently
reported symptoms concerned
sensory losses and changes in the
face, lips or tongue (12 reports,
Table 2). Not a single report was
received concerning these symp-
toms in association with other
dental local anaesthetics.
Discussion
Haas and Lennon reported in
1995 (2), that there were Cana-
dian reports of a higher risk than
expected of sensory changes in-
volved in local mandibular (low-
er jaw) anaesthesia using arti-
caine. A researcher (3) who had
reassessed these reports claimed
that the risk with articaine
would be as much as 20 times
higher than that with lidocaine.
Malamed et al. (4) compared the
adverse reactions that had oc-
curred in 1,325 patients with lo-
cal infiltration or nerve block
anaesthesia using either 4% arti-
caine or 2% lidocaine and
claimed that the frequency of
sensory losses and changes (4–8
days after local anaesthesia) was
1% with both the local anaes-
thetics used. In this study the
symptoms were reversible.
The Danish drug authorities
reviewed the spontaneous reports
of sensory losses associated with
the use of articaine and conclud-
ed that there is no proof so far of
any greater neurotoxicity being
associated with articaine in com-
parison with other local anaes-
thetics (5). Hillerup et al. (1) car-
ried out a review of 52 patients,
who were afflicted with nerve
damage in association with a lo-
cal mandibular anaesthetic.
These patients experienced lin-
gual nerve damages more fre-
quently and with more compli-
cated symptoms than inferior
alveolar nerve damage. In this
patient material 4% articaine
caused 54% of the nerve dam-
ages, but the researchers did not
make a relative comparison be-
tween the extent of the damage
and the number of local anaes-
thetics given.
Based on the data received
from the studies so far it is im-
possible to produce an accurate
estimate of the extent of risk of
sensory losses or changes in-
volved with the use of articaine.
However, it appears to be an un-
common adverse reaction and
there is no certainty that the risk
with articaine-containing prod-
ucts would be higher than with
other local anaesthetics.
There have also been reports
of sensory loss or of changes as-
sociated with the use of articaine
in Finland. The total number of
reports is 12. Some patients ex-
hibited symptoms up to 6
months after the administration
of the local anaesthesia. The
symptoms can be hard to handle,
including for example speech dif-
ficulties or alterations in the
sense of taste as a result of a sen-
sory loss, making life therefore
difficult. There was a likelihood
in at least four cases that the ad-
verse reactions were not associat-
ed with articaine contained in the
local anaesthetic (Table 2). The
senses of feeling focussed on the
eye and the observations made at
the opposite side of the face indi-
cate that the anaesthetic agent
has been transmitted to an incor-
rect area. The unwanted reac-
tions focussing in the area of the
eye as such are possible for ex-
ample in the local anaesthesia of
an upper canine tooth. Anaesthe-
sia of the ocular motor nerve can
affect the extraocular muscles,
the movement of the upper eyelid
(manifested especially as a diffi-
culty of keeping the eye open)
and contraction of the pupil. An
accelerated pulse and malaise are
known sympathetic effects of
adrenaline when the local anaes-
thetic enters the blood circula-
tion. Fear of treatment may also
cause or aggravate similar symp-
toms in patients.
Conclusions cannot be drawn
based on the adverse drug reac-
tion reports received by NAM in
respect to the incidence of these
reactions, because not all adverse
reactions are reported – especial-
ly not the transient types, which
the majority of the sensory losses
caused by local anaesthetics are.
It is recommended that the
healthcare personnel should bear
in mind the meaning of the re-
ports of adverse reactions while
information is being compiled re-
lating to the adverse reactions, as
this information is helpful in
making important observations
about the safety of use of medi-
cines at the population level.
Table 1. Adverse reactions caused by local anaesthetic products containing articaine and 
adrenaline reported to the ADR register of NAM.
Adverse reaction Number of 
reports
Sensory losses or changes in the face, lips or the tongue                                 13
Nausea or vomiting 11
Urticaria or other rash 9
Anaphylaxis 8
Palpitations 8
Oedema of the face, mouth or the pharynx 6
Somnolence, fatigue or hypotonia 4
Injection site reaction 4
Dizziness 4
Syncope 4
Dyspnoea 3
Convulsions 3
Other 5
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The Finnish material and in-
ternational studies suggesting that
articaine would increase the risk
of sensory losses or changes at
most give guidance, and there is
no reliable evidence of the neuro-
toxicity of articaine. It is suggest-
ed, nevertheless, that at the high-
er concentration articaine-con-
taining products can cause a
higher risk of nerve damage (1).
Consequently, in the use of arti-
caine-containing and other local
dental anaesthetics effort should
be made to keep the injected dose
of the anaesthetic as low as possi-
ble by using careful anaesthetic
techniques.
See literature on page 26.
Table 2.  Reports which included a mention of a sensory loss or change in association with the use of a local anaesthetic containing articaine 
and adrenaline.
Patient Description of the adverse reaction
1) A 24-year-old female The local anaesthetic used was Ultracain D-Suprarenin (no information about the dose or the method of admi-
nistration). The patient had an odd feeling in the eye, difficulties in keeping the eye open and a glassy pupil on 
the side other than that injected with the local anaesthetic. The adverse reaction was possibly due to the 
anaesthetic technique used or to anatomical variations, and in consequence the role of the local anaesthetic
in causing the adverse reaction is unclear.
2) A 3-year-old boy 1.7 ml injection of Ubistesin was followed by a severe burning pain in the tongue and the lip on the left side, 
i.e. anaesthesia was not achieved in the intended area. The pain was relieved after a while at home.  
3) A 58-year-old male Local infiltration anaesthesia due to root treatment of d35 (1 ampoule of Ultracain D-Suprarenin). Half a year 
later, sensory loss remained in the left lower jaw. 
4) A 29-year-old female Local infiltration anaesthesia in the mucous membrane at d17 (Ubistesin 1.7 ml). After about 10 minutes, a 
feeling of anaesthesia in a wider area than expected developed together with malaise and palpitations. 
The symp toms were probably caused by adrenaline.
5) A 24-year-old female Local infiltration anaesthesia in the mucous membranes at d15 (Ubistesin 1.7 ml). A feeling of anaesthesia in 
a wide area, malaise, palpitations and light-headedness followed. The symptoms were probably caused by 
adrenaline.
6) A 26-year-old female Immediately following local nerve block anaesthesia in the lower jaw (Ubistesin 1.7 ml), there was contraction 
of the surface vessels of the left side of the face and anaesthesia of the upper eyelid. The symptoms dis-
appeared within a couple of minutes, the probable cause of them being adrenaline. 
7) A 52-year-old female Local nerve block anaesthesia in the left lower jaw (Ultracain D-Suprarenin 1.7 ml). The tongue was still 
anaesthetized and stiff 2.5 months later. 
8) A 47-year-old male A local anaesthetic (Ultracain D-Suprarenin 3.4 ml) was given due to root treatment of d36, which was fol-
lowed by sensory loss in the lip and cheek on the left side. Gradually the sense of feeling in the cheek became 
hypersensitive, and the feeling returned to normal a couple of months after the administration of the local 
anaesthetic. 
9) A 34-year-old female The total Ubistesin used was less than 3 x 1.7 ml for  local infiltration anaesthesia due to root treatment of d27.  
A feeling of anaesthesia in the cheek continued for 4 weeks following treatment. A couple of months later a 
small area in the cheek developed hypersensitivity to touching. The sense of feeling later returned to normal. 
10) A 46-year-old female The patient had undergone surgery for the removal of d37, the local anaesthetic used was Ubistesin 1.7 ml 
and  there was no special sense of feeling during local anaesthesia. Following the procedure, however, the lip 
and the tongue remained anaesthetized, including a feeling of odd stinging and itching, but no aching. The 
tongue has no sense of taste on the left side, and the tongue gets tired while the patient is talking, making 
talking laborious. 
11) A 31-year-old female Local nerve block anaesthesia (Ubistesin 1.7 ml) due to filling of d46. Within the next few days following 
anaesthesia the entire right side of the tongue still felt anaesthetized, and three weeks later the sense of taste
at the back of the right side of the tongue was still absent.
12) A 40-year-old female Local nerve block anaesthesia with Ubistesin 1.7 ml due to surgery of d36. The left side of the face was anaes-
thetized to the extent that the left eye would not close at all. The duration of effect of the local anaesthetic 
agent was 5-6 hours. The tactile sensitivity in the left cheek thereafter was less than that in the right cheek.
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NAM’s marketing authorisation
department was restructured in
2003 in order to streamline mar-
keting authorisation processes
and promote pursuit of the
strategic aims of the NAM.
Thanks to the restructuring, con-
siderable progress was made in
terms of achieving these aims. It
became gradually clear, neverthe-
less, that old working methods
still prevailed while new tasks
were adopted. Consequently, the
handling of processes was not
sufficiently improved in order to
achieve clearing the ever-growing
backlog of applications.
Applications since 2000  
Finland was flooded with nation-
al marketing authorisation appli-
cations for generic medicinal
products, especially in the years
after 2000. The biggest waves of
applications came in the years
2004 to 2005. Marketing autho-
risation holders of these products
regularly request that Finland
(NAM) becomes the European
reference member state for their
products. A statement was issued
by NAM on its website in 2005
in which the backlog of applica-
tions was openly admitted and
applicants were asked to explore
other routes, particularly where
their product was not actually in-
tended for the Finnish market.
This act reduced the annual num-
ber of national marketing autho-
risation applications (Fig. 1).
At the same time, the total num-
ber of other marketing authorisa-
tion applications, applications for
variations and notifications has
continued to grow rapidly (Fig. 2).
Goals of the marketing 
authorisation department
The processing of applications is
governed, among other things, by
dead lines stipulated in the Medi-
cines Act and Decree. NAM is
expected to be an active player in
the EU Regulatory Network for
medicinal products, to promote
healthy pharmaceutical markets,
to facilitate electronic submis-
sions, and improve the availabili-
ty of independent drug informa-
tion. In light of the present work
situation and available resources,
it is, however, very challenging to
achieve this target.
Strategic means  
Nationally, it is very important to
ensure compliance with the stipu-
lations of the Medicines Act, to
ensure the maintenance of exper-
tise in drug regulation and drug
development in Finland, and to
promote Finnish national inter-
ests in the EU. The marketing au-
thorisations department aims to
facilitating work sharing among
national competent authorities.
There is a desire to put more
trust in the work of other nation-
al agencies, and to comply with
mutually agreed guidelines. 
The processing of marketing
authorisation applications is sim-
plified through the avoidance of
repeated requests for additional
information in the national pro-
cedures and  of rounds of  for
comments and responses in the
mutual recognition and decen-
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tralised procedures. The praxis
that the authorities will check
everything and will finally fix the
deficiencies must be abandoned.
Optimum use of expert resources
is achieved by prioritising tasks
in respect of drug safety.
Electronic submission and
management of regulatory infor-
mation, electronic submission of
marketing authorisation applica-
tions in particular will be intro-
duced. This will improve the run-
ning of operations and the asso-
ciated monitoring of work flow,
and will also release resources
from several tasks which until
now have been carried out man-
ually. The aim is to adopt a ser-
vice-based operational model for
marketing authorisation issues
where the processes and cus-
tomer relationships form the key
guiding factors. Information on
the NAM website relating to the
marketing authorisation system
will be expanded and updated.
NAM wants to do its part to
ensure the availability of generic
drugs not only nationally, but al-
so throughout the European
Union area, and thereby to pro-
mote the fair sharing of work as
well as mutual trust among
member states. This is the only
way of solving the work over-
load situation with which all
member states are struggling.
As part of the centralised
marketing authorisation proce-
dure, the European Medicines
Agency (EMEA) grants evalua-
tion (reporting) duties to national
agencies in accordance with their
expertise and experience. NAM
works actively within its area of
specialisation in order to main-
tain its level of competitiveness. 
In the regulatory work, we
need to focus increasingly on the
availability of medicinal prod-
ucts, and to support drug devel-
opment (e.g. scientific advice). As
Finland is a small market area,
we often encounter problems in
availability of important medici-
nal products, including veteri-
nary medicinal products. Safe-
guarding the disease-free state
and public health issues associat-
ed with animals in commercial
production are key issues to con-
sider in the field of veterinary
medicinal products.
The job descriptions of per-
sonnel in the marketing authori-
sation department are being up-
graded to meet the future chal-
lenges. The need to develop com-
petence according to the needs of
the organisation from the indi-
vidual starting points of each
member of the personnel will be
given ever more emphasis in fu-
ture. The multidisciplinary ap-
proach to the evaluation work is
promoted.
Organisational and 
operational changes
In 2007, five sections of the mar-
keting authorisation department
were reorganised to leave just
three, namely the Sections for In-
novative, Generic and Veterinary
Medicines. This reorganisation
improved the effectiveness of
management operations by mak-
ing a distinction between man-
agerial and expert roles. The
tasks of the Sections for Innova-
tive and Generic Medicines were
expanded. The department in-
cludes a management group with
the task of synchronisation of the
work in the three sections, pro-
moting scientific expertise for
centralised EU processes, man-
agement of development projects
and legal/administrative policy
making. 
The Section for Innovative
Medicines processes all applica-
tions relating to brand-name
drugs. The work of all 35 em-
ployees in the section focuses
mainly on the management of
rapporteur/co-rapporteur duties
as part of the centralised proce-
dure as well as certain national,
mutual recognition and de-cen-
tralised marketing authorisation
applications. The section is also
responsible for national and
EMEA scientific advise and for
the evaluation of herbal medici-
nal products. Experts of this sec-
tion are also involved in the
work of the new paediatric com-
mittee which was set up and
commenced operation in July
2007. A degree relating to ad-
vanced therapies, which is set to
become effective as of next year,
will also create new responsibili-
ties for the section.
Since the reorganisation, the
section has focused on stabilising
operations and clearing the back-
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log of national applications. Col-
laboration with the generic drugs
section has been intensified and
both sections have set their sites
on achieving effective, standard-
ised processes.
The Section for Generic Med-
icines was expanded at the begin-
ning of 2007 to include parallel
imports and distribution, as well
as some of the joint processes
and development tasks of the
marketing authorisation depart-
ment. The section has approxi-
mately 40 employees. All sorts of
generic drugs are now managed
in the same section, and opera-
tions supporting common depart-
ment issues are best suited to this
section. During 2007 the generic
drugs section has also stabilised
its operations. There are now
fewer changes in personnel and
the section is well on its way to
clearing the backlog.
The structure of the Section
for Veterinary Medicines remains
unchanged. This section can be
best described as the NAM in
miniature, because its operations
include several functions which
with regard to human medicines
have been divided into different
departments. Besides marketing
authorisation applications, the
section for veterinary medicines
also deals with notifications of
clinical trials on veterinary medi-
cinal products, special licences
for the release of a veterinary
medicinal products and pharma-
coviglilance. The section takes
part in EU collaboration in the
European Medicines Agency.
Regulation of veterinary medi-
cines is linked to significant na-
tional interests relating to public
health and the disease-free status
of the production animals. There
is currently a delay in the pro-
cessing of applications for re-
newals and variations. The sec-
tion is relieving its own backlog
by prioritising the marketing au-
thorisation application process,
which is carried out in a straight-
forward fashion, avoiding repeat
requests for additional reports.
Monitoring of the processes  
By its nature, NAM’s marketing
authorisation application process
produces an abundance of data
and statistics, but to interpret
these in such a way as to moni-
tor processes meaningfully has
proven difficult for many rea-
sons: the process contains several
phases and a number of opera-
tors, with bottlenecks developing
at different stages at different
times. Furthermore, the work-
load of different expert groups
cannot be measured using the
same standards. A process track-
ing system has been developed to
solve these problems. Possibilities
for monitoring personal perfor-
mance and workload have also
been improved. New, easy-to-use
monitoring instruments will be
introduced by the end of the
year.
In 2005, NAM introduced a
system for monitoring the time
spent for various tasks by its per-
sonnel. The system also provides
information regarding the costs
of core operations. Managers at
different levels use these data  for
monitoring and ensuring proper
targeting of resources. The data
obtained from this system have
made it possible to assess the hu-
man resources needed for the
project for cutting queues.    
Regulatory guidance
Scientific evaluation of medicinal
products is conducted according
to NAM’s standard operation
procedures. The guidelines start
from the premise that the aim
should be for Finland to recog-
nise marketing authorisations
evaluated by a reference member
state, and that only in exception-
al cases should Finland object to
the scientific evaluation of a
medicinal product by a reference
member state in the marketing
authorisation process (only in
case of a justified potential seri-
ous risk to human or animal
health or to the environment).
Furthermore, standard opera-
tional procedures aim to bring
clarity to the interactions be-
tween the applicant and NAM.
This is achieved by accelerating
the inquiry and hearing proceed-
ings stipulated in administrative
legislation so that hearing pro-
ceedings can start immediately, if
the application for marketing au-
thorisation is immature. At the
stage of the marketing authorisa-
tion process where the applicant
has the opportunity to reply to
an inquiry by NAM, the inten-
tion is that one round should be
sufficient for the decision mak-
ing. If this response is not ade-
quate, the application is to be re-
jected on grounds of immaturity.
The revised Medicines Direc-
tive includes an article called the
Sunset Clause, which is imple-
mented in subparagraph 3, para-
graph 1 of Section 29 of the
Medicines Act (395/87). Accord-
ing to this article, the marketing
authorisation and registration
will become invalid if the mar-
keting authorisation holders have
not introduced the product onto
the market within 3 years of the
marketing authorisation or regis-
tration being granted, or if the
presence of the product on the
market has been continuously in-
terrupted for three years. Amend-
ed Section 29 of the Medicines
Act (395/87) came into force on
7.11.2005. The legal implications
of the statute on marketing au-
thorisations of medicinal prod-
ucts will become effective as of
7.11.2008. According to the
view adopted by NAM, this sec-
tion of the legislation will not be
applicable to products which
have been granted marketing au-
thorisation via the centralised
procedure, nor will it be applica-
ble to medicinal products with
parallel import licences.
A statement prepared in re-
sponse to the Sunset Clause is
published on NAM’s website.
The bulletin on the website in-
cludes additional guidance for
marketing authorisation holders
regarding interpretation of the
various concepts, time schedules,
methods of operation, etc.
Electronic management of
regulatory information
The chief project in NAM’s elec-
tronic management of regulatory
information is the change to elec-
tronic processing of marketing
authorisations. The main aim of
the project for the marketing au-
thorisation department is to
make operations more effective
and to facilitate handling
through the simplification and
acceleration of the various stages
of the processes. Tendering for
delivery of the electronic man-
agement system is underway, and
the project is expected to be up
and running at the beginning of
2008. Collaboration with stake-
holder groups forms an impor-
tant part of the scheme.
Special project for clearing
the backlog of applications 
At the end of February 2007,
NAM set up a 2-year project
called ‘JoPo’ to clear the back-
logs of applications. The project
got off to a good start. By the
end of November, over 50% of
the applications designated as
part of the project had already
been processed. The progress of
the project is monitored very
closely.
Effects of the new regulatory
policy  
The aim of the new policy  and
associated measures is to priori-
tise and improve the scientific
evaluation as well as coordina-
tion and processing of marketing
authorisation applications. The
implications that this will have to
marketing authorisation appli-
cants and holders are reflected,
for example, in the reinforcement
of the regulatory i.e. supervisory
role of the authority. A good ap-
plication will pass through the
process quickly, while a bad one
will not pass through at all. Pri-
mary responsibility for the quali-
ty and user-friendliness of the
SPCs and package leaflets lies
with the marketing authorisation
applicants and holders. Pharma-
ceutical companies must realise
that the authorities are not able
to take on the burden of editing
poor-quality documents to the
stage where they can be ap-
proved. This work must be car-
ried out by the pharmaceutical
companies themselves, with the
only alternative being rejection of
the applications. Prescribers and
users of medicinal products
should become accustomed to the
fact that the product information
for medicinal products, e.g.
generic products, assessed by oth-
er competent authorities may in
some cases differ from that of the
local innovator medicinal prod-
uct which was originally ap-
proved in Finland. Switching to
electronic submissions requires
that applicants start using the
eCTD format.
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cations in the project. NP = national procedure, MRP = mutual recognition, DCP= de-centralised procedure.
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